Aasa J, Hu Y, Eklund G, Lindgren A, Baranczewski P, Malmquist J, Turek D, and Bueters T
(2013) Effect of solvents on the time-dependent inhibition of CYP3A4 and the
biotransformation of AZD3839 in human liver microsomes and hepatocytes. Drug Metab
Dispos 41:159–169.
Agoram B, Woltosz WS, and Bolger MB (2001) Predicting the impact of physiological and
biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50.
Albaugh DR, Fullenwider CL, Fisher MB, and Hutzler JM (2012) Time-dependent inhibition and
estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human
cell systems. Drug Metab Dispos 40:1336–1344.
Andersin R (1991) Solubility and acid-base behaviour of midazolam in media of different pH,
studied by ultraviolet spectrophotometry with multicomponent software. J Pharm Biomed
Anal 9:451–455.
Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, and
Sada T (2015) Pharmacological profile of CS-3150, a novel, highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. Eur J Pharmacol 761:226–234.
Arai K, Morikawa Y, Ubukata N, Tsuruoka H, and Homma T (2016) CS-3150, a novel
nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects
on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. J Pharmacol
Exp Ther 358:548–557.
113
Arai K, Tsuruoka H, and Homma T (2015) CS-3150, a novel non-steroidal mineralocorticoid
receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive
hypertensive rats. Eur J Pharmacol 769:266–273.
Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its
relationship to physicochemical properties. 33:419–425.
Backman JT, Aranko K, Himberg JJ, and Olkkola KT (1994) A pharmacokinetic interaction
between roxithromycin and midazolam. Eur J Clin Pharmacol 46:551–555.
Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, and Hall SD (2002) The
effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A
activity. Sekisui Medical Co., Ltd. Research Report. 2016;No. GE-1416-G (Daiichi Sankyo
Report No. AM15-C0070-R01). Br J Clin Pharmacol 53:67–74.
Biradar S V., Patil AR, Sudarsan G V., and Pokharkar VB (2006) A comparative study of
approaches used to improve solubility of roxithromycin. Powder Technol 169:22–32.
Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions
from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor
absorption rate constant. Br J Clin Pharmacol 60:508–518.
Chang SY, Chen C, Yang Z, and Rodrigues AD (2009) Further assessment of 17alpha-ethinyl
estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab
Dispos 37:1667–1675.
Chantot J, Bryskier A, and Gasc J (1986) Antibacterial activity of roxithromycin: a laboratory
evaluation. J Antibiot 39:660–668.
114
Cook JA, Randinitis EJ, Bramson CR, and Wesche DL (2006) Lack of a pharmacokinetic
interaction between azithromycin and chloroquine. Am J Trop Med Hyg 74:407–412.
Cui D, Cabalu T, Yee KL, Small J, Li X, Liu B, Maciolek C, Smith S, Liu W, McCrea JB, and
Prueksaritanont T (2016) In vitro and in vivo characterisation of the metabolism and
disposition of suvorexant in humans. Xenobiotica 46:882–895.
Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li
J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, MacGregor TR, and Kashuba
AD (2010) A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug
interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther
87:735–742.
Edgar B, Lundborg P, and Regårdh CG (1987) Clinical Pharmacokinetics of Felodipine. Drugs 34
Suppl 3:16–27.
Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A,
Hyland R, and Obach RS (2009) Comparison of different algorithms for predicting clinical
drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds
as precipitants of interaction. Drug Metab Dispos 37:1658–1666.
Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model
for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition,
inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698–1708.
Fee JPH, Collier PS, Howard PJ, and Dundee JW (1987) Cimetidine and ranitidine increase
midazolam bioavailability. Clin Pharmacol Ther 41:80–84.
Fleishaker JC, and Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the
combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35–39.
115
Food and Drug Administration (2020) In Vitro Drug Interaction Studies — Cytochrome P450
Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, US
Department of Health and Human Services Center for Drug Evaluation and Research, FDA,
Silver Spring, MD.
Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2010) Selection of alternative CYP3A4
probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
Drug Metab Dispos 38:981–987.
Furuie H, Toyama K, Okuda Y, Kuroda K, Shimizu T, Kato M, and Ishizuka H (2019) The effect
of multiple oral administration of esaxerenone on the pharmacokinetics of midazolam in
healthy Japanese males. Eur J Clin Pharmacol 75:Supple 1:S38.
Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the
prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909–922.
Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB (2007) Maximal inhibition of intestinal
first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug
interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685–693.
Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution
in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180–190.
Gascon MP, and Dayer P (1991) In vitro forecasting of drugs which may interfere with the
biotransformation of midazolam. Eur J Clin Pharmacol 41:573–578.
GastroPlus 9.7 Manual (2019) . Simulations Plus, Inc.
Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, and Galetin A
(2013) Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux
116
transporters: application of PBPK Modeling in the assessment of drug-drug interaction
potential. Pharm Res 30:761–780.
Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass
metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug
Metab Dispos 38:1147–1158.
Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of
intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug
Metab Dispos 39:1633–1642.
Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB,
Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, and Lewis LD (2010) An evaluation of the
drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor
tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with
advanced solid tumors. Clin Pharmacol Ther 88:652–659.
Greenblatt DJ (2014) In vitro prediction of clinical drug interactions with CYP3A substrates: we
are not there yet. Clin Pharmacol Ther 95:133–135.
Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, and Wang Y (2019) Physiologically
based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and
Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci 108:21–25.
Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, and Galetin A (2011) Critique of the twofold measure of prediction success for ratios: Application for the assessment of drug-drug
interactions. Drug Metab Dispos 39:170–173.
117
Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, and Galetin A (2011)
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms:
comparison of dynamic and static models. Br J Clin Pharmacol 71:72–87.
Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J,
Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A, and Consortium IT (2018)
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro,
Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol
Ther 104:865–889.
Haarhoff ZE, Kramer MA, Zvyaga TA, Zhang J, Bhutani P, Subramanian M, and Rodrigues AD
(2017) Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A)
inhibition: comparison of cynomolgus monkey and human. Xenobiotica 47:470–478.
Hallifax D, and Houston J (2006) Binding of drugs to hepatic microsomes: comment and
assessment of current prediction methodology with recommendation for improvement. Drug
Metab Dispos 34:724–726.
Hang TJ, Zhang M, Song M, Shen JP, and Zhang YD (2007) Simultaneous determination and
pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by
LC-MS/MS. Clin Chim Acta 382:20–24.
Heath EI, Forman K, Malburg L, Gainer S, Suttle AB, Adams L, Ball H, and LoRusso P (2012) A
phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as
crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs
30:1566–1574.
118
Heikkinen AT, Baneyx G, Caruso A, and Parrott N (2012) Application of PBPK modeling to
predict human intestinal metabolism of CYP3A substrates - An evaluation and case study
using GastroPlusTM. Eur J Pharm Sci 47:375–386.
Hsueh CH, Hsu V, Pan Y, and Zhao P (2018) Predictive performance of physiologically-based
pharmacokinetic models in predicting drug–drug interactions involving enzyme modulation.
Clin Pharmacokinet 57:1337–1346.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of
pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the
liver. Pharmacol Rev 50:387–412.
Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, and Yamakawa S (2020) Double-Blind
Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients
With Essential Hypertension (ESAX-HTN Study). Hypertension 75:51–58, Am Heart
Assoc.
Ito S, Shikata K, Nangaku M, Okuda Y, and Sawanobori T (2019) Efficacy and safety of
esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a
randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol 14:1161–
1172.
Itoh H, Ito S, Rakugi H, Okuda Y, and Nishioka S (2019) Efficacy and safety of dosage-escalation
of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2
diabetes and albuminuria: a single-arm, open-label study. Hypertens Res 42:1572–1581.
Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of Pravastatin, Simvastatin,
and Atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol
94:1140–1146.
119
Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M,
and Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and
development: a pharmaceutical industry perspective. Clin Pharmacol Ther 97:247–262.
Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, and Ishizuka H (2018) Single‐and
multiple‐dose escalation study to assess pharmacokinetics, pharmacodynamics, and safety
of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol 84:1821–1829.
Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, and Mikus G (2011) Determining
the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors
using a limited sampling strategy. Clin Pharmacol Ther 90:666–673.
Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, and Khojasteh SC (2012) Drugdrug interaction potential of marketed oncology drugs: In vitro assessment of time-dependent
cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction
prediction. Pharm Res 29:1960–1976.
Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2011)
Complex Drug Interactions of HIV Protease Inhibitors 1 : Inactivation , Induction , and
Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. 39:1070–1078.
Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T,
Nishikawa Y, and Ishizuka H (2020a) Effects of itraconazole and rifampicin on the singledose pharmacokinetics of the non-steroidal mineralocorticoid receptor blocker esaxerenone in
healthy Japanese subjects. Br J Clin Pharmacol doi: 10.1111/bcp.14302.
Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T,
Nishikawa Y, and Ishizuka H (2020b) Pharmacokinetic interactions of esaxerenone with
amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacol Toxicol In press.
120
Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, and Watanabe H (2009) Effects of statins
on the pharmacokinetics of midazolam in healthy volunteers. J Clin Pharmacol 49:568–573.
Kurata A, Furuie H, Ishizuka T, Nakatsu T, Shimizu T, Kato M, Nishikawa Y, and Ishizuka H
(2019) Absolute bioavailability of esaxerenone and food effects on its pharmacokinetics after
a single oral dose in healthy japanese subjects: an open-label crossover study. Adv Ther
36:1618–1627.
Kwon JW, and Armbrust KL (2008) Aqueous solubility, n-octanol-water partition coefficient, and
sorption of five selective serotonin reuptake inhibitors to sediments and soils. Bull Environ
Contam Toxicol 81:128–135.
Lam YWF, Alfaro CL, Ereshefsky L, and Miller M (2003) Pharmacokinetic and
Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine,
Fluvoxamine, and Nefazodone. J Clin Pharmacol 43:1274–1282.
Liu B, Crewe HK, Ozdemir M, Rowland Yeo K, Tucker G, and Rostami-Hodjegan A (2017) The
absorption kinetics of ketoconazole plays a major role in explaining the reported variability in
the level of interaction with midazolam: Interplay between formulation and inhibition of gut
wall and liver metabolism. Biopharm Drug Dispos 38:260–270.
Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini
G, Liric Rajlic I, and Obach RS (2013a) Comprehensive assessment of human
pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J
Clin Pharmacol 53:178–191.
Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini
G, Liric Rajlic I, and Obach RS (2013b) Comprehensive assessment of human
121
pharmacokinetic prediction based on in vivo animal pharmacokinetic data , part 1: volume of
distribution at steady state. J Clin Pharmacol 53:167–177.
Mao J, Tay S, Khojasteh CS, Chen Y, Hop CE, and Kenny JR (2016) Evaluation of time
dependent inhibition assays for marketed oncology drugs: comparison of human hepatocytes
and liver microsomes in the presence and absence of human plasma. Pharm Res 33:1204–
1219.
Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E,
O’Reilly TE, Butterton JR, and Yeh WW (2017) No clinically meaningful pharmacokinetic
interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral
contraceptives ethinyl estradiol and levonorgestrel. Eur J Clin Pharmacol 73:593–600.
Mathews D, McNutt B, Okerholm R, Flicker M, and McBride G (1991) Torsades de pointes
occurring in association with terfenadine use. JAMA 266:2375–2376.
Mc Donnell CG, Shorten G, and Van Pelt FN (2005) Effect of atorvastatin and fluvastatin on the
metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 60:747–753.
Motta P, Pons N, Pagliarusco S, Pellegatti M, and Bonomo F (2011) Casopitant: in vitro data and
SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450
3A4. Drug Metab Dispos 39:363–372.
Nishiya Y, Nakamura K, Okudaira N, Abe K, Kobayashi N, and Okazaki O (2010) Effects of
organic solvents on the time-dependent inhibition of CYP3A4 by diazepam. Xenobiotica
40:1–8.
Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug
interactions. J Pharmacol Exp Ther 316:336–348.
122
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human
intestinal cytochrome P450 “pie.” Drug Metab Dispos 34:880–886.
Pellegatti M, Bordini E, Fizzotti P, Roberts A, and Johnson BM (2009) Disposition and
metabolism of radiolabeled casopitant in humans. Drug Metab Dispos 37:1635–1645.
Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, Urva S, Anak O,
Sellami D, and Kobalava Z (2013) Effects of Hepatic Impairment on the Pharmacokinetics of
Everolimus: A Single-Dose, Open-Label, Parallel-Group Study. Clin Ther 35:215–225.
Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, and Hochman J (2013)
Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J
15:629–645.
Rakugi H, Ito S, Itoh H, Okuda Y, and Yamakawa S (2019) Long-term phase 3 study of
esaxerenone as mono or combination therapy with other antihypertensive drugs in patients
with essential hypertension. Hypertens Res 42:1932–1941.
Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H,
Payne CD, Forgue ST, Eckstein J, Wrighton SA, and Phillips DL (2005) Effect of tadalafil on
cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo. Clin Pharmacol Ther
77:63–75.
Rostami-Hodjegan A, and Tucker G (2004) “In silico” simulations to assess the “in vivo”
consequences of “in vitro” metabolic drug-drug interactions. Drug Discov Today Technol
1:441–448.
Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, and Tucker GT (2011) Prediction
of time-dependent CYP3A4 drug-drug interactions by physiologically based
123
pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover. Eur J
Pharm Sci 43:160–173.
Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden
MR, Jensen CB, Wrighton SA, Smith BP, Read HA, and Witcher JW (2004) Atomoxetine
hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther
308:410–418.
Serajuddin AT, Ranadive SA, and Mahoney EM (1991) Relative lipophilicities, solubilities, and
structure‐pharmacological considerations of 3‐hydroxy‐3‐methylglutaryl‐coenzyme
A (HMG‐CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J
Pharm Sci 80:830–834.
Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy
VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C,
Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A,
Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, and Rowland
M (2018) Physiologically based pharmacokinetic model qualification and reporting
procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther
104:88–110.
Skerjanec A, Wang J, Maren K, and Rojkjaer L (2010) Investigation of the pharmacokinetic
interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and
repaglinide in healthy volunteers. J Clin Pharmacol 50:205–213.
Snyder BD, Rowland A, Polasek TM, Miners JO, and Doogue MP (2014) Evaluation of
felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin
Pharmacol 70:1115–1122.
124
Thompson PD, Priscilla C, and Karas RH (2003) Statin-associated myopathy. JAMA 289:1681–
1690.
Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996)
Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic
CYP3A‐mediated metabolism. Clin Pharmacol Ther 59:491–502.
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL,
McVicar JP, Barr DM, Perkins JD, and Carithers RL (1994) Use of midazolam as a human
cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J
Pharmacol Exp Ther 271:549–556.
Tiseo PJ, Perdomo CA, and Friedhoff LT (1998) Concurrent administration of donepezil HCl and
cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J
Clin Pharmacol 46 Suppl 1:25–29.
Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, Vlase L, Gheldiu AM, and Briciu
C (2016) Evaluation of a potential metabolism-mediated drug-drug interaction between
atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci 19:198–207.
Tsunoda SM, Velez RL, Von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal
and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect
of ketoconazole. Clin Pharmacol Ther 66:461–471.
Urva S, Bouillaud E, Delaney R, Jappe A, and Cheung W (2013) A phase I study evaluating the
effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin
Pharmacol 53:444–450.
125
van Crugten J, Bochner F, Keal J, and Somogyi A (1986) Selectivity of the cimetidine-induced
alterations in the renal handling of organic substrates in humans. Studies with anionic,
cationic and zwitterionic drugs. J Pharmacol Exp Ther 236:481–487.
Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V,
Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys
J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds
KS, and Huang SM (2014) Evaluation of various static in vitro-in vivo extrapolation models
for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin
Pharmacol Ther 95:189–198.
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, and Shader RI (1994) In vitro prediction of
the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222–1227.
von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and Shader RI
(1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by
fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783–791.
Wu K, Xu J, Fong R, Yao X, Xu Y, Guiney W, Gray F, and Lockhart A (2016) Evaluation of the
safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a
selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers. Int J Clin Pharmacol Ther
54:935–949.
Yamada M, Mendell J, Takakusa H, Shimizu T, and Ando O (2019) Pharmacokinetics,
metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker
in humans. Drug Metab Dispos 47:340–349.
Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, Murayama N, Inoue S, and
Izumi T (2017) Pharmacokinetics, distribution, and disposition of esaxerenone, a novel,
126
highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and
monkeys. Xenobiotica 47:1090–1103.
Yamazaki T, Desai A, Goldwater R, Han D, Lasseter KC, Howieson C, Akhtar S, Kowalski D,
Lademacher C, Rammelsberg D, and Townsend R (2017) Pharmacokinetic Interactions
Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin,
Metformin, and Methotrexate in Healthy Subjects. Clin Pharmacol Drug Dev 6:66–75.
Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, and Tucker GT (2007) Misuse of the wellstirred model of hepatic drug clearance. Drug Metab Dispos 35:501–502.
Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal
first-pass drug metabolism. Curr Drug Metab 8:676–684.
Yeates RA, Laufen H, and Zimmermann T (1996) Interaction between midazolam and
clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 34:400–405.
Yu H, and Tweedie D (2013) A Perspective on the contribution of metabolites to drug-drug
interaction potential: the need to consider both circulating levels and inhibition potency. Drug
Metab Dispos 41:536–540.
Zamuner S, Johnson BM, Pagliarusco S, Fina P, Peroni M, Fiore M, Adams LM, and Fernandes
SA (2010) Effect of single and repeat doses of casopitant on the pharmacokinetics of
CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol 70:537–546.
Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009) Semiphysiologically based
pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major
metabolite. Drug Metab Dispos 37:1587–1597, ASPET.
127
Zhi J, Moore R, Kanitra L, and Mulligan TE (2003) Effects of orlistat, a lipase inhibitor, on the
pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in
healthy volunteers. J Clin Pharmacol 43:428–435.
Zimmerlin A, Trunzer M, and Faller B (2011) CYP3A time-dependent inhibition risk assessment
validated with 400 reference drugs. Drug Metab Dispos 39:1039–1046.
イトリゾールカプセル添付文書 (2017) . 2017年7月改訂（第28版）.
セララ錠添付文書 (2019) . 2019年9月改訂（第1版）.
ベルソムラ錠添付文書 (2020) . 2020年1 月改訂（第7 版）.
厚生労働省 (2018) 医薬品開発と適正な情報提供のための薬物相互作用ガイドライン.
日本医療薬学会 (2019) 医療現場における薬物相互作用へのかかわり方ガイド.
128
...
論文の公開元へ
